Background: There are limited data on the epidemiology, diagnosis and optimal management of nontuberculous mycobacterial (NTM) disease in children.

Methods: Retrospective cohort study of NTM cases over a 10-year-period at a tertiary referral hospital in Australia.

Results: A total of 140 children with NTM disease, including 107 with lymphadenitis and 25 with skin and soft tissue infections (SSTIs), were identified. The estimated incidence of NTM disease was 0.6-1.6 cases / 100,000 children / year; no increasing trend was observed over the study period. Temporal analyses revealed a seasonal incidence cycle around 12 months, with peaks in late winter/spring and troughs in autumn. Mycobacterium-avium-complex accounted for most cases (77.8%), followed by Mycobacterium ulcerans (14.4%) and Mycobacterium marinum (3.3%). Polymerase chain reaction testing had higher sensitivity than culture and microscopy for acid-fast bacilli (92.0%, 67.2% and 35.7%, respectively). The majority of lymphadenitis cases underwent surgical excision (97.2%); multiple recurrences in this group were less common in cases treated with clarithromycin and rifampicin compared with clarithromycin alone or no anti-mycobacterial drugs (0% versus 7.1%; OR:0.73). SSTI recurrences were also less common in cases treated with two anti-mycobacterial drugs compared with one or none (10.5% versus 33.3%; OR:0.23).

Conclusions: There was seasonal variation in the incidence of NTM disease, analogous to recently published observations in tuberculosis, which have been linked to seasonal variation in vitamin D. Our finding that anti-mycobacterial combination therapy was associated with a reduced risk of recurrences in patients with NTM lymphadenitis or SSTI requires further confirmation in prospective trials.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727903PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0147513PLOS

Publication Analysis

Top Keywords

ntm disease
16
nontuberculous mycobacterial
8
epidemiology diagnosis
8
incidence ntm
8
common cases
8
cases treated
8
anti-mycobacterial drugs
8
seasonal variation
8
ntm
6
cases
6

Similar Publications

In vitro susceptibility of 147 international clinical Mycobacterium abscessus isolates to epetraborole and comparators by broth microdilution.

J Antimicrob Chemother

December 2024

Division of Mycobacterial and Respiratory Infections, Department of Medicine, National Jewish Health, Denver, CO, USA.

Background: Mycobacterium abscessus is a highly drug-resistant non-tuberculous mycobacterium (NTM) for which treatment is limited by the lack of active oral antimycobacterials and frequent adverse reactions. Epetraborole is a novel oral, boron-containing antimicrobial that inhibits bacterial leucyl-tRNA synthetase, an essential enzyme in protein synthesis, and has been shown to have anti-M. abscessus activity in preclinical studies.

View Article and Find Full Text PDF

Introduction The prevalence of nontuberculous mycobacteria (NTM) is higher in patients with structural lung disease and in immunocompromised patients. Lung involvement is the most common. The complex corresponds to the most identified agent.

View Article and Find Full Text PDF

Berberine enhances the antibacterial activity of thymoquinone, carvacrol and thymol against multi-drug resistant nontuberculous mycobacteria.

Pol J Vet Sci

September 2024

Department of Biology and Fish Diseases, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Akademicka 12, 20-033 Lublin, Poland.

The aim of this study was to investigate the activity of thymoquinone (TQ), carvacrol (CAR) and thymol (TYM) against multi-drug resistant nontuberculous mycobacteria (MDR-NTM), alone and in combination with berberine (BER). Antimicrobial activity was first evaluated at concentrations from 8 to 512 μg/mL. Each of the compounds tested exhibited good activity against nontuberculous mycobacteria (NTM) isolated from fish, with MIC values of 32-128 μg/mL.

View Article and Find Full Text PDF

The Molecular Bacterial Load Assay predicts treatment responses in patients with pre-XDR/XDR-tuberculosis more accurately than GeneXpert Ultra MTB/Rif.

J Infect

December 2024

German Center for Infection Research (DZIF), Partner site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany; Division of Clinical Infectious Diseases, Research Center Borstel, Parkallee 1-40, 23845 Borstel, Germany.

Objectives: Early detection of treatment failure is essential to improve the management of drug-resistant tuberculosis (DR-TB). We evaluated the molecular bacterial load assay (MBLA) in comparison to standard diagnostic tests for monitoring therapy of patients affected by drug-resistant TB.

Methods: The performance of MBLA in tracking treatment response in a prospective cohort of patients with pulmonary MDR/RR- and pre-XDR/XDR-TB was compared with mycobacterial culture, mycobacterial DNA detection using GeneXpert (Xpert) and microscopy detection of sputum acid-fast-bacilli.

View Article and Find Full Text PDF

Background: The usefulness of bronchoscopy for the diagnosis of NTM pulmonary disease (NTM-PD) has been reported. However, performing bronchoscopy for aspirated sputum and airway secretion specimens (sputum aspirate specimens) in the region extending from the trachea down to the orifice of each segmental bronchus has been poorly documented. We evaluated the diagnostic yield of sputum aspirate specimens collected from the central airway using bronchoscopy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!